These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2189281)

  • 41. Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites.
    McGuire JL; Phillips A; Hahn DW; Tolman EL; Flor S; Kafrissen ME
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2127-31. PubMed ID: 2124088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.
    Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH
    Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Third generation progestagens].
    Belaisch J; Eliakim V
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):287-93. PubMed ID: 12318226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women.
    Kuhnz W
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2120-7. PubMed ID: 2124087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of pharmaceutical compounds on male fertility.
    Neumann F; Diallo FA; Hasan SH; Schenck B; Traore I
    Andrologia; 1976; 8(3):203-35. PubMed ID: 793446
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High inhibitory activity of R 5020, a pure progestin, at the hypothalamic-adenohypophyseal level on gonadotropin secretion.
    Labrie F; Ferland L; Lagace L; Drouin J; Asselin J; Azadian-Boulanger G; Raynaud JP
    Fertil Steril; 1977 Oct; 28(10):1104-12. PubMed ID: 71251
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of a biodegradable contraceptive capsule (Capronor) containing levonorgestrel on gonadotropin, estrogen, and progesterone levels.
    Ory SJ; Hammond CB; Yancy SG; Hendren RW; Pitt CG
    Am J Obstet Gynecol; 1983 Mar; 145(5):600-5. PubMed ID: 6402933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of desogestrel.
    McClamrock HD; Adashi EY
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1021-8. PubMed ID: 8447355
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro.
    Rabe T; Kowald A; Ortmann J; Rehberger-Schneider S
    Gynecol Endocrinol; 2000 Aug; 14(4):223-30. PubMed ID: 11075290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
    Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
    Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women.
    Kuhnz W; Blode H; Mahler M
    Contraception; 1994 Mar; 49(3):255-63. PubMed ID: 8200219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Preclinical research and development of norethisterone].
    Mcguire JL; Hahn DW; Philipps A
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):437-44. PubMed ID: 12280212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive.
    Upton GV; Corbin A
    Yale J Biol Med; 1989; 62(5):445-57. PubMed ID: 2534253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical profile of contraceptive progestins.
    Benagiano G; Primiero FM; Farris M
    Eur J Contracept Reprod Health Care; 2004 Sep; 9(3):182-93. PubMed ID: 15697108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical results with subcutaneous implants containing 3-keto desogestrel.
    Olsson SE; Odlind V; Johansson E
    Contraception; 1990 Jul; 42(1):1-11. PubMed ID: 2117514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.